No abstract

Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) are all blood borne pathogens that are still global health challenges and were known to be endemic in Nigeria. Little work had been done on Hepatitis-B and C co-infection among HIV positive patients in the three Senatorial Districts of Rivers State. A case- control, hospital- based study was conducted among subjects from Rivers state University Teaching Hospital (RSUTH), Zonal Hospital, Bori and Zonal Hospital, Ahoada to determine the prevalence of Hepatitis B and C co-infection in these areas. Three hundred and seventy-five subjects of (10-69 years) and both sexes were included in the study. A structured questionnaire was administered to obtain demographic parameters of the participants. The samples collected were screened and confirmed for hepatitis-B and C using standard techniques. The overall prevalence rates of HBV, HCV and HBV/HCV in this study are 4.5%, 2.1% and 0.8% respectively while the prevalence among HIV positive participants were; 4.6%, 2.8% and 1.1% respectively. Bori had the highest prevalence of HBV and HCV, (5.3% and 4.2%) while Ahoada had the highest prevalence of triple infection (2.1%). The prevalence of HIV/HBV, HIV/HCV and HIV/HBV/HCV infection was more among subjects within age range of 30-39 years (7.0%, 5.6% and 4.2%) and lowest within the age range of 20-29 years (2.3%, 0% and 0%). Conclusively, the research findings show that the prevalence of hepatitis B and C co-infection among HIV patients in these hospitals are high. Thus, every HIV positive patient should be screened and educated on the danger of co-infection for better management of the patient.

PurposeHydroxychloroquine (HCQ) is an important medication for patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases. Although it is well-tolerated and cost-effective, the risk of HCQ retinal toxicity is of increasing concern. The aim of this study is to re-examine the HCQ retinal toxicity incidence rate, risk factors and clinical course after discontinuation.MethodsWe designed a prospective population-based cohort study in adult patients with SLE or RA, currently receiving HCQ for five or more years, who are residents of British Columbia (BC), Canada. Based on administrative data, we identified 5508 eligible participants (1346 SLE and 4162 RA). They will participate in annual or biannual retinal screening over 5 years in alignment with the recently revised American Academy of Ophthalmology guidelines. To standardise procedures for retinal screening, imaging, diagnostic criteria, severity staging and data transfer, a consensus meeting was convened in December 2019 with participation of BC retinal specialists and the research team. Agreement was attained on: use of spectral domain-optical coherence tomography as the primary objective screening modality; classification of images into categories of normal, equivocal or abnormal; and transferring the equivocal and abnormal images plus corresponding subjective test results via cloud-based server from each clinic to a reading centre. Confirmation of HCQ retinal toxicity diagnoses and severity staging will be performed by three independent and masked reviewers. The incidence of HCQ retinal toxicity will be calculated, accounting for the competing risk of death. Hazard ratios for each risk factor will be calculated for the risk of HCQ retinopathy, after adjusting for confounders. We will also estimate the risk of HCQ retinal toxicity progression over 5 years.Ethics and disseminationThis study has received approval from the University of British Columbia Clinical Research Ethics Board (H20-00736) and the Vancouver Coastal Health Research Institute.

A cross-sectional investigation of hepatitis-B status among attendees of Modern Primary Health Centre, Eneka and Rivers State University Teaching Hospital, Port Harcourt was evaluated. Seven hundred (700) subjects of different ages of both sexes were included in the study after ethical approval was obtained from the Rivers State Ministry of Health, Port Harcourt. Consent forms were issued to get subjects’ consent before questionnaire administration to obtain their demographic data. The uninfected subjects were used as control. About 4mls of blood was taken from each subject by vein-puncture; 2mls each was dispensed into EDTA and plain bottles for analysis. The samples were used to assay for hepatitis-B surface antigen (HBsAg), hepatitis–B virus (HBV) markers (HBsAb, HBeAg, HBeAb, HBcAb) using standard techniques. The overall prevalence of HBV was 5.1% in Port Harcourt. The males had higher prevalence of 7.9% HBV than the females 3.4% HBV, although there was no statistically significant difference (P ≥0.05). The HBV was highest among subjects of age group 24-29 years (8.29%) and 30-35 years (9.2%) accordingly. The HBV markers results show that while HBsAg occurred among all the subjects that were positive for HBV, HBeAb was completely absent.